Hoang C Dang
Examiner (ID: 12651)
Most Active Art Unit | 3506 |
Art Unit(s) | 3506, 2731, 3625, 3672 |
Total Applications | 3000 |
Issued Applications | 2548 |
Pending Applications | 156 |
Abandoned Applications | 295 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18921501
[patent_doc_number] => 20240024505
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => SYNTHETIC CELLULAR SIGNALING PATHWAYS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/221206
[patent_app_country] => US
[patent_app_date] => 2023-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50084
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18221206
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/221206 | SYNTHETIC CELLULAR SIGNALING PATHWAYS AND USES THEREOF | Jul 11, 2023 | Pending |
Array
(
[id] => 18709190
[patent_doc_number] => 20230331802
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => METHOD TO PREPARE THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/344130
[patent_app_country] => US
[patent_app_date] => 2023-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18344130
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/344130 | METHOD TO PREPARE THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS | Jun 28, 2023 | Pending |
Array
(
[id] => 19310490
[patent_doc_number] => 12036284
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-16
[patent_title] => Compositions and methods of treatment for severe hypertriglyceridemia
[patent_app_type] => utility
[patent_app_number] => 18/340421
[patent_app_country] => US
[patent_app_date] => 2023-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 46
[patent_no_of_words] => 32164
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 196
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18340421
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/340421 | Compositions and methods of treatment for severe hypertriglyceridemia | Jun 22, 2023 | Issued |
Array
(
[id] => 18656210
[patent_doc_number] => 20230302094
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => GLP-1 RECEPTOR AGONISTS IN DEMENTIA
[patent_app_type] => utility
[patent_app_number] => 18/208485
[patent_app_country] => US
[patent_app_date] => 2023-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13601
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18208485
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/208485 | GLP-1 RECEPTOR AGONISTS IN DEMENTIA | Jun 11, 2023 | Pending |
Array
(
[id] => 18673135
[patent_doc_number] => 20230310616
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/331197
[patent_app_country] => US
[patent_app_date] => 2023-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30032
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -86
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18331197
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/331197 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | Jun 7, 2023 | Pending |
Array
(
[id] => 18752458
[patent_doc_number] => 20230355709
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => Lyophilized Formulation
[patent_app_type] => utility
[patent_app_number] => 18/331318
[patent_app_country] => US
[patent_app_date] => 2023-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18587
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18331318
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/331318 | Lyophilized Formulation | Jun 7, 2023 | Pending |
Array
(
[id] => 18837718
[patent_doc_number] => 11845781
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-19
[patent_title] => Fusion protein comprising fibroblast growth factor 19 (FGF 19) and glucagon-like peptide-1
[patent_app_type] => utility
[patent_app_number] => 18/181666
[patent_app_country] => US
[patent_app_date] => 2023-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 8
[patent_no_of_words] => 3963
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18181666
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/181666 | Fusion protein comprising fibroblast growth factor 19 (FGF 19) and glucagon-like peptide-1 | Mar 9, 2023 | Issued |
Array
(
[id] => 18511376
[patent_doc_number] => 20230227521
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => PRODRUGS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/099282
[patent_app_country] => US
[patent_app_date] => 2023-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20594
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 204
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18099282
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/099282 | Prodrugs and uses thereof | Jan 19, 2023 | Issued |
Array
(
[id] => 19354099
[patent_doc_number] => 12054528
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-06
[patent_title] => Co-agonists of the GLP-1 and amylin receptors
[patent_app_type] => utility
[patent_app_number] => 18/084088
[patent_app_country] => US
[patent_app_date] => 2022-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 183
[patent_figures_cnt] => 183
[patent_no_of_words] => 31621
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18084088
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/084088 | Co-agonists of the GLP-1 and amylin receptors | Dec 18, 2022 | Issued |
Array
(
[id] => 18733578
[patent_doc_number] => 11802301
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-31
[patent_title] => Compositions and methods for peptide production
[patent_app_type] => utility
[patent_app_number] => 18/063064
[patent_app_country] => US
[patent_app_date] => 2022-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 26
[patent_no_of_words] => 18256
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 351
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18063064
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/063064 | Compositions and methods for peptide production | Dec 6, 2022 | Issued |
Array
(
[id] => 18322469
[patent_doc_number] => 20230120597
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY
[patent_app_type] => utility
[patent_app_number] => 17/980990
[patent_app_country] => US
[patent_app_date] => 2022-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15586
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17980990
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/980990 | CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY | Nov 3, 2022 | Abandoned |
Array
(
[id] => 18916731
[patent_doc_number] => 11879001
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-23
[patent_title] => Conjugate comprising an IL-2 moiety
[patent_app_type] => utility
[patent_app_number] => 18/052495
[patent_app_country] => US
[patent_app_date] => 2022-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 102218
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 146
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052495
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052495 | Conjugate comprising an IL-2 moiety | Nov 2, 2022 | Issued |
Array
(
[id] => 18340100
[patent_doc_number] => 20230132049
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => ANTIBODIES BINDING TO CD30 AND CD3
[patent_app_type] => utility
[patent_app_number] => 17/938523
[patent_app_country] => US
[patent_app_date] => 2022-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31181
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938523
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/938523 | Antibodies binding to CD30 and CD3 | Oct 5, 2022 | Issued |
Array
(
[id] => 18413156
[patent_doc_number] => 11667689
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-06
[patent_title] => Insulin-Fc fusion proteins and methods of use to treat cancer
[patent_app_type] => utility
[patent_app_number] => 17/814285
[patent_app_country] => US
[patent_app_date] => 2022-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 21873
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 145
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814285
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/814285 | Insulin-Fc fusion proteins and methods of use to treat cancer | Jul 21, 2022 | Issued |
Array
(
[id] => 17958692
[patent_doc_number] => 20220339272
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 17/853344
[patent_app_country] => US
[patent_app_date] => 2022-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48385
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17853344
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/853344 | Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells | Jun 28, 2022 | Issued |
Array
(
[id] => 18683928
[patent_doc_number] => 11779638
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-10
[patent_title] => Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
[patent_app_type] => utility
[patent_app_number] => 17/853334
[patent_app_country] => US
[patent_app_date] => 2022-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 22
[patent_no_of_words] => 48788
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17853334
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/853334 | Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells | Jun 28, 2022 | Issued |
Array
(
[id] => 18427647
[patent_doc_number] => 11672848
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-13
[patent_title] => Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
[patent_app_type] => utility
[patent_app_number] => 17/852623
[patent_app_country] => US
[patent_app_date] => 2022-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 22
[patent_no_of_words] => 48796
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17852623
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/852623 | Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells | Jun 28, 2022 | Issued |
Array
(
[id] => 17981268
[patent_doc_number] => 20220347304
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => Therapeutic Derivatives of Interleukin-22
[patent_app_type] => utility
[patent_app_number] => 17/737849
[patent_app_country] => US
[patent_app_date] => 2022-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20126
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17737849
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/737849 | Therapeutic derivatives of interleukin-22 | May 4, 2022 | Issued |
Array
(
[id] => 17850571
[patent_doc_number] => 20220280612
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => GLP-1 RECEPTOR AGONISTS IN DEMENTIA
[patent_app_type] => utility
[patent_app_number] => 17/736116
[patent_app_country] => US
[patent_app_date] => 2022-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13576
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736116
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/736116 | GLP-1 RECEPTOR AGONISTS IN DEMENTIA | May 3, 2022 | Abandoned |
Array
(
[id] => 17805904
[patent_doc_number] => 20220257739
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 17/728756
[patent_app_country] => US
[patent_app_date] => 2022-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48531
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17728756
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/728756 | Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells | Apr 24, 2022 | Issued |